# Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

> **NCT03712943** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 52 (actual)

## Conditions studied

- Colorectal Cancer
- Metastatic Colorectal Cancer
- Colon Cancer

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03712943
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-23
- **Primary completion:** 2021-09-01
- **Final completion:** 2024-01-18
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-02-09

## Collaborators

- Bristol-Myers Squibb

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03712943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03712943, "Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03712943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*